Adrenal steroidogenesis inhibitors

Adrenal steroidogenesis inhibitors comprise a group of drugs that reduce the synthesis of steroid hormones produced by the adrenal cortex by selectively or relatively selectively blocking key enzymes in the biosynthetic pathway. In clinical endocrinology, their main use is the control of endogenous hypercortisolism, particularly when surgery cannot be performed immediately, has not been curative, is still awaiting its full effect or must be supported by bridging medical therapy. In more selected settings, these drugs may also be used in adrenocortical carcinoma, in severe forms of Cushing's syndrome requiring rapid biochemical control and, in specific circumstances, to limit adrenal androgen excess.

The aim of treatment is not simply to “lower cortisol”, but to achieve a controlled reduction in toxic hormonal exposure that disrupts metabolism, the cardiovascular system, immunity, bone health, neuropsychiatric balance and thromboembolic risk, while avoiding the development of iatrogenic adrenal insufficiency. The principles governing this therapeutic class depend on the physiology of steroidogenesis, the point in the biosynthetic pathway at which blockade occurs, the speed of drug action, the potential accumulation of precursors with mineralocorticoid or androgenic activity and the need to translate biochemical control into genuine clinical benefit.

The adrenal cortex synthesises glucocorticoids, mineralocorticoids and androgens from cholesterol through an ordered sequence of enzymatic reactions involving, among others, CYP11A1, CYP17A1, 3β-HSD, CYP21A2, CYP11B1 and, in specific settings, CYP11B2. Steroidogenesis inhibitors act by blocking one or more steps in this pathway, thereby reducing production of the final hormone that is pathologically excessive. In practice, their clinical value derives from the ability to act rapidly on the gland's secretory product, regardless of whether the underlying disorder is pituitary, ectopic or adrenal in origin.

In Cushing's syndrome, the rationale is straightforward: organ damage is largely driven by chronic exposure to inappropriate cortisol concentrations. Reducing cortisol therefore means interrupting or attenuating a biological signal that promotes hyperglycemia, hypertension, visceral obesity, sarcopenia, skin fragility, osteoporosis, immune dysfunction, cognitive impairment and increased cardiovascular and infection-related mortality. Effective treatment, however, does not mean achieving the greatest possible degree of enzyme inhibition, but rather reaching a balance in which hypercortisolism is controlled without causing an excessive fall in physiological glucocorticoid signalling.

A fundamental endocrinological consideration is that steroidogenesis blockade does not switch off the upstream pathogenic signal. If Cushing's syndrome is ACTH-dependent, the reduction in cortisol may remove negative feedback and promote an increase in ACTH, with precursor accumulation and possible enhancement of steroid synthesis through shunted pathways. This explains why certain drugs, although effective in controlling cortisol, may promote adverse effects such as hypokalemia, hypertension, androgenisation or accumulation of 11-deoxycorticosterone and 11-deoxycortisol, depending on the inhibited enzyme.

Beyond hypercortisolism, the rationale extends to more selected settings. In adrenocortical carcinoma, mitotane exerts not only an inhibitory effect on steroidogenesis but also an adrenolytic effect, making it an integral part of a complex oncological strategy. In some forms of congenital adrenal hyperplasia or refractory adrenal androgen excess, CYP17A1 blockade with abiraterone may reduce androgen synthesis, although this use remains highly specialised and is not part of routine general practice. In summary, steroidogenesis inhibitors are drugs that translate the biosynthetic pathophysiology of the adrenal cortex into a measurable and powerful treatment that may also be hazardous unless managed systematically.

The drugs in this class differ primarily in the point of the biosynthetic pathway that they inhibit. Metyrapone and osilodrostat act predominantly on 11β-hydroxylase, reducing the final conversion step leading to cortisol. Ketoconazole and levoketoconazole exert broader effects on several steroidogenic enzymes, including CYP17A1 and CYP11A1, resulting in an overall reduction in cortisol synthesis as well as androgen and gonadal steroid production. Mitotane has a different biological profile because, in addition to interfering with steroidogenesis, it exerts selective cytotoxic activity on the adrenal cortex. Finally, etomidate is the only parenteral inhibitor that can be administered intravenously in severe hypercortisolism when oral treatment is not possible or is not sufficiently rapid.

These differences result in markedly different pharmacological and clinical profiles. By blocking the terminal phase of cortisol synthesis, metyrapone and osilodrostat tend to reduce cortisol rapidly but may promote the accumulation of upstream precursors with mineralocorticoid activity and, particularly with metyrapone in women, increased androgen synthesis through collateral pathways. Ketoconazole, because of its multi-enzyme blockade, has an almost opposite rationale: it reduces cortisol but also tends to reduce androgens, making it potentially useful in patients in whom hyperandrogenism is a clinically relevant problem. The price of this broader action, however, is a greater risk of hepatotoxicity and drug interactions related to cytochrome P450 inhibition.

Osilodrostat is distinguished by its high potency, longer half-life than metyrapone and strong ability to normalise cortisol in many patients with Cushing's disease. However, this efficacy makes cautious titration essential to avoid iatrogenic hypocortisolism. Levoketoconazole, the enantiomer of ketoconazole, was developed to improve predictability and efficacy, but it remains within the same clinical paradigm of a drug requiring careful hepatic, electrocardiographic and metabolic monitoring.

Mitotane deserves separate consideration. It is not merely a drug that reduces steroidogenesis, but an adrenolytic agent with a long latency, substantial tissue accumulation, complex pharmacokinetics and the ability to increase glucocorticoid metabolism, often making higher replacement doses necessary in patients who develop adrenal insufficiency. Etomidate, by contrast, is a drug for critical-care settings: its usefulness derives from its rapid intravenous action and the possibility of controlling severe hypercortisolism in intensive care or other monitored settings, but its use requires experience and close supervision. The pharmacology of this class is therefore not a collection of dose equivalents, but a map of biological profiles that guide drug selection according to urgency, pathophysiological mechanism and patient comorbidities.

Treatment with steroidogenesis inhibitors first requires a clear definition of the clinical setting in which the drug is being introduced. In most patients with Cushing's syndrome, surgery for the causal lesion remains the first-line strategy, but there are many situations in which medical control of cortisol is required before surgery, between surgical procedures, after surgical failure, while awaiting the effects of radiotherapy or as long-term treatment when curative alternatives are unavailable or not tolerated. Initial drug selection therefore depends on the severity of hypercortisolism, the desired speed of action, the adverse-effect profile and the individual characteristics of the patient.

Titration may follow two general strategies. The first is a stepwise approach, in which treatment begins with a low or intermediate dose that is gradually increased until biochemical and clinical control is achieved. This approach reduces the risk of iatrogenic adrenal insufficiency but may be too slow in more severe disease. The second is the block-and-replace strategy, in which a more complete blockade of steroidogenesis is initially achieved and glucocorticoid replacement therapy is subsequently introduced to provide predictable and safe exposure. This approach is particularly useful in marked or highly fluctuating hypercortisolism, but requires greater clinical experience and closer monitoring.

The choice of individual drug also depends on the pattern of associated clinical features. In a patient with Cushing's syndrome and severe hypokalemia, metyrapone or osilodrostat may rapidly correct cortisol levels but, if not carefully titrated, may worsen precursor-mediated mineralocorticoid retention. In a woman with hypercortisolism and clinically significant hyperandrogenism, ketoconazole may be preferable because of its broader inhibitory effect on steroid synthesis. If the disease is fulminant, with psychosis, severe infection, metabolic decompensation or inability to take oral medication, etomidate is the most appropriate intensive bridging treatment. In adrenocortical carcinoma, by contrast, mitotane forms part of a different strategy in which the target is not merely biochemical but also oncological.

Proper treatment initiation therefore does not consist simply of “prescribing an inhibitor”, but of constructing a dynamic plan that includes close reassessment, predefined thresholds for dose adjustment, tolerability monitoring and a clear strategy for early recognition of the transition from hypercortisolism to glucocorticoid deficiency. In this therapeutic class, success depends as much on the selected drug as on the precision with which the transition between pathological hormone excess and normal physiology is managed.

Monitoring of steroidogenesis inhibitors must answer two questions simultaneously: has cortisol been reduced sufficiently to protect the patient from the toxic effects of hypercortisolism and, at the same time, is treatment avoiding iatrogenic adrenal insufficiency? Follow-up therefore cannot rely on a single parameter. Clinical assessment, urinary free cortisol, serum or salivary cortisol depending on the setting, blood glucose, blood pressure, potassium, body weight, signs of residual hypercortisolism and the onset of symptoms suggestive of hypocortisolism, such as nausea, marked fatigue, hypotension, abdominal pain or sudden deterioration in general well-being, must all be integrated.

Interpretation of laboratory tests must take the specific drug into account. With CYP11B1 inhibitors such as metyrapone and osilodrostat, accumulation of 11-deoxycortisol may interfere with some cortisol immunoassays. When available, more specific methods such as mass spectrometry or expert laboratory interpretation are therefore preferable. This is clinically important because an apparent “normal” or “high” cortisol result may partly reflect analytical interference and lead to inappropriate dose adjustments.

Biochemical monitoring must be accompanied by drug-specific toxicity surveillance. Ketoconazole and levoketoconazole require particular attention to liver function and, in selected settings, to the QT interval and drug interactions. Metyrapone and osilodrostat require monitoring of potassium, blood pressure and signs of mineralocorticoid or androgenic precursor excess. Mitotane requires even more complex monitoring, including plasma drug concentrations, liver function, neurological status, lipid profile and adequacy of glucocorticoid replacement. Etomidate, used in acute settings, requires intensive monitoring of cortisol, neurological status and hemodynamic parameters.

Finally, monitoring must establish whether biochemical improvement translates into genuine clinical improvement. Reducing cortisol without seeing a progressive correction of hypertension, hyperglycemia, hypokalemia, edema, proximal weakness and susceptibility to infection should prompt consideration of whether control remains inadequate, is too recent to have produced benefit or has been achieved at the cost of poorly tolerated treatment. Effective monitoring does not merely pursue a number, but seeks a measurable reduction in organ damage caused by cortisol excess.

Variability in the response to steroidogenesis inhibitors depends on pharmacokinetic, pharmacodynamic and biological factors. A crucial component is represented by drug interactions, particularly with ketoconazole and levoketoconazole, which substantially inhibit cytochrome P450 enzymes and may therefore increase exposure to numerous concomitant drugs, including antiarrhythmics, psychotropic drugs, anticoagulants, immunosuppressants and other compounds with potential effects on the QT interval or liver. In these patients, treatment must always be assessed systemically because an adverse event may result not from the endocrine drug alone but from the network of interactions it creates.

With metyrapone and osilodrostat, the main problem is not an external metabolic interaction but the accumulation of precursors upstream of the enzymatic block. Increased 11-deoxycortisol and 11-deoxycorticosterone may cause hypertension and hypokalemia, while increased ACTH, in ACTH-dependent disease, may further stimulate the adrenal gland and promote collateral synthetic pathways. With metyrapone, this more readily results in increased androgen synthesis, with acne, hirsutism and worsening of female hyperandrogenism. Osilodrostat, because of its potency and duration of action, may more readily produce a rapid transition to adrenal insufficiency if titration is too aggressive.

Mitotane introduces a further level of complexity because it increases glucocorticoid metabolism and alters the distribution of steroids and lipophilic drugs. As a result, the patient may require higher-than-expected glucocorticoid replacement doses and may show a discrepancy between apparently “adequate” doses and clinical signs of under-replacement. Furthermore, the long time required to achieve therapeutic concentrations and the tissue persistence of the drug make the response less predictable and less rapidly reversible than with other inhibitors.

Management of interactions therefore follows a precise sequence: first, the drug most consistent with the clinical setting is selected; then, the risk of specific toxicity is assessed; concomitant therapy is reviewed; and finally, the clinical response is interpreted in the light of the precursor profile that each drug tends to generate. Steroidogenesis inhibitors are effective when the clinician does not merely observe the fall in cortisol but understands the “new steroid balance” that the drug is creating in the individual patient.

In patients with severe or rapidly progressive hypercortisolism, the absolute priority is to reduce cortisol quickly because the immediate risk of infectious, thromboembolic, metabolic and psychiatric events outweighs the risk of potential iatrogenic adrenal insufficiency, provided that the latter is recognised promptly. In this setting, medical treatment is not merely supportive but an organ-saving and, at times, life-saving intervention. Intravenous etomidate and combinations of oral inhibitors are the most useful options in critical settings.

In ectopic forms of Cushing's syndrome, which are often characterised by very high cortisol levels, marked hypokalemia and rapid clinical deterioration, steroidogenesis inhibitors have a particularly important role because they allow cortisol control even when the ACTH-secreting tumour cannot be located or treated immediately. These patients more often require an intensive approach, and block-and-replace regimens or drug combinations are used more frequently than in less aggressive forms.

In adrenocortical carcinoma, mitotane occupies a distinct position. It is not selected simply as a steroidogenesis inhibitor, but as a drug with oncological and adrenolytic activity that contributes both to controlling hormone hypersecretion and to the antitumour strategy. This setting requires expert centres, plasma level monitoring and careful management of the endocrine consequences of adrenal destruction, including the need for glucocorticoid and sometimes mineralocorticoid replacement.

A more specialised area concerns congenital adrenal hyperplasia and other forms of adrenal androgen excess. In these settings, CYP17A1 blockade with abiraterone may reduce androgen production and allow a reduction in the supraphysiological glucocorticoid doses required to suppress ACTH. However, this is a highly specialised use, not standardised to the same degree as Cushing's syndrome treatment, and it requires management of effects on the mineralocorticoid and gonadal compartments. More generally, use of these drugs during pregnancy and in paediatric patients requires even greater caution and specialist case-by-case assessment.

Most patients begin treatment with monotherapy selected according to their clinical profile, but modern endocrinological practice increasingly uses combination strategies when cortisol control must be rapid, when the response to a single drug is incomplete or when adverse effects limit further dose escalation. Combining drugs that act on different enzymes may provide an additive effect on hypercortisolism control while reducing the need to push each individual compound towards more toxic doses.

The block-and-replace strategy is the clearest application of this approach. Rather than pursuing cortisol control through small progressive adjustments, a more decisive blockade of adrenal production is induced and glucocorticoid replacement at physiological or near-physiological doses is introduced. The advantage is greater predictability of cortisol exposure; the disadvantage is that the clinician must manage two processes simultaneously: inhibition of steroidogenesis and replacement of the essential glucocorticoid signal. This method is particularly useful in patients with severe or fluctuating hypercortisolism, but requires experience, patient education and close monitoring.

Another strategic use of these drugs is as bridging therapy. Before surgery, reducing cortisol may improve blood glucose, blood pressure, potassium, infectious status and thromboembolic risk, making the patient more stable for anesthesia and the postoperative period. After non-curative surgery or while awaiting the effects of pituitary radiotherapy, steroidogenesis inhibitors make it possible to control organ damage until definitive treatment becomes effective. In some situations, they also represent long-term chronic treatment for patients who cannot undergo surgery or who decline more invasive procedures.

In summary, advanced strategies are not pharmacological shortcuts, but different ways of translating the physiology of steroidogenesis into sustainable clinical control. Monotherapy, combination treatment, intensive etomidate, block-and-replace and oncological mitotane are distinct tools that share the same underlying rule: reduce pathological cortisol exposure without losing control of the physiology that is essential for survival.

The most important overarching risk of this drug class is iatrogenic adrenal insufficiency. Any drug capable of effectively reducing cortisol may cross the equilibrium point and precipitate clinically significant glucocorticoid deficiency. The problem is particularly insidious because nausea, weakness, abdominal pain, fatigue and worsening well-being may be misinterpreted as manifestations of residual hypercortisolism or nonspecific effects of the underlying disease. Prevention therefore requires patient education, readiness to temporarily stop or reduce the dose and, when appropriate, timely initiation of replacement therapy.

In addition to this shared risk, there are drug-specific toxicities. Ketoconazole and levoketoconazole primarily raise concerns about hepatic toxicity, as well as drug interactions and, in some settings, QT prolongation. Metyrapone and osilodrostat more commonly cause accumulation of mineralocorticoid precursors, leading to hypokalemia and hypertension, while metyrapone may worsen hyperandrogenism. Mitotane has a broader toxicity profile, with neurological, gastrointestinal and metabolic effects, as well as prolonged persistence that makes excessive exposure more difficult to correct rapidly. Finally, etomidate requires a monitored setting precisely because the speed of its action demands close surveillance of the transition from hypercortisolism to deficiency.

Safety also depends on the ability to interpret the clinical context. In a patient with severe hypercortisolism, a rapid fall in cortisol may be necessary and appropriate, whereas in a patient with less aggressive disease the same rate of reduction may be excessive. Similarly, hepatic impairment, heart disease, predisposition to arrhythmias, psychiatric vulnerability or polypharmacy substantially alter the risk-benefit profile of the individual drug.

Prevention of iatrogenic harm therefore rests on four actions: selecting the drug according to pathophysiology and comorbidities, monitoring biochemical control at an early stage, promptly recognising signs of glucocorticoid deficiency and never underestimating organ-specific toxicities. Steroidogenesis inhibitors are powerful and valuable drugs, but they require a level of supervision proportionate to their efficacy.

The real-world effectiveness of steroidogenesis inhibitors depends largely on adherence, but in this drug class adherence does not merely mean taking tablets regularly. It also means understanding why close monitoring is required, why certain symptoms must be reported immediately and why the dose may change rapidly during the first few weeks. Without this education, the patient may interpret early improvement as permanent stabilisation or, conversely, may underestimate signs of hypocortisolism until overt adrenal insufficiency develops.

Patient education should include at least three concepts. First, the therapeutic target is not always immediately perceptible because some complications of hypercortisolism improve rapidly, whereas others, such as sarcopenia, bone fragility or cognitive impairment, take longer. Second, symptoms such as nausea, dizziness, hypotension, worsening fatigue or fever may indicate an excessive reduction in glucocorticoid signalling and require prompt medical contact. Third, quality of life truly improves when cortisol control produces a sustainable reduction in organ damage, not when a single “normal” test result is achieved at the cost of toxicity or therapeutic instability.

A common problem is the persistence of nonspecific symptoms even after partial biochemical control. In such cases, automatically attributing every symptom to an insufficient drug dose may lead to overcorrection and iatrogenic harm. The clinician must instead distinguish among residual damage from hypercortisolism, established metabolic and cardiovascular comorbidities, depression, physical deconditioning and emerging iatrogenic adrenal insufficiency. This integrated interpretation prevents pharmacological treatment from becoming a reflex response to every unresolved symptom.

Finally, good adherence is built through simple but rigorous rules: knowing when tests should be performed, which concomitant drugs must be reported, which signs should prompt an earlier consultation and under what circumstances treatment may need to be temporarily interrupted or glucocorticoid coverage initiated. When these rules are shared, steroidogenesis inhibitors become an effective tool not only for lowering cortisol, but also for restoring a quality of life less dominated by the systemic effects of hypercortisolism.